Arguably the most likely candidate genes for cannabis use disorders are those encoding the cannabinoid receptors. These receptors form the binding sites for endogenous cannabinoids, such as anadamide (N-arachidonyl-ethanolamine), 2-AG (2-archidonyl-glycerol) [25-27] and the more recently identified noladin (2-archidonyl-glyceryl ether), virhodamine (O-arachidonoyl-ethanolamine) and NADA (N-arachidonoyl dopamine) [28-30].
